Abstract: A test circuit board adapted to be used on USB connector is provided. Two test circuit boards can be seriously connected with each other through a first JTAG connection interface and a second JTAG connection interface. Therefore, the efficiency of reducing TAPs of TAP controller and providing test signal coverage of all of test signals may be achieved.

Abstract: A test circuit board adapted to be used on PCI-E slot is provided. Two test circuit boards can be seriously connected with each other through a first JTAG connection interface and a second JTAG connection interface. Therefore, the efficiency of reducing TAPs of TAP controller and providing test signal coverage of all of test signals may be achieved.

Abstract: Embodiments of the present invention relate to adaptive audio capturing. A method for adaptive audio capturing is disclosed. The method comprising obtaining an audio signal through an audio channel associated with an audio capturing element on a user terminal; calculating a signal amplitude for the audio channel by processing the obtained audio signal; and determining a functionality of the audio capturing element based on the signal amplitude and a further signal amplitude for at least one further audio channel associated with at least one further audio capturing element on the user terminal. Corresponding apparatus, computer program product, and user terminal are also disclosed.

Abstract: Described are ROR? modulators of the formula (I), or pharmaceutically acceptable salts thereof, wherein all substituents are defined herein. The invention includes stereoisomeric forms of the compounds of formula I, including stereoisomerically-pure, scalemic and racemic form, as well as tautomers thereof. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.

Abstract: Described are ROR? modulators of the formula (I), [INSERT CHEMICAL STRUCTURE HERE] or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.

Abstract: Aspects of the disclosure provide a circuit. The circuit includes a switch and a switch controller. The switch is between a first node that receives a first power supply and a second node, and is controlled to couple/decouple the second node with the first node to switch on/off a second power supply at the second node. The switch controller is configured to generate a switch control signal to control a charging current flowing through the switch to switch on the second power supply.

Abstract: An improved hair brush having a prism shaped brush head, such as a cylindrical brush head, with spaced apart brush tips or tufts of bristles distributed around a portion of the 360° of the outer surface. The spaced apart brush tips or bristles may be present in only ? (i.e. 120°) to ½ (i.e. 180°) of the entire outer surface, or it may cover more or less than this range to improve the smoothing or curling of a user's hair. Each tuft of bristles may have different lengths and randomly be directed at different directions.

Abstract: Electrical equipment includes a power supply unit, a signal receiving unit, a rectifying and filtering unit, a switch unit, and a control. The rectifying and filtering unit rectifies and filters remote signals received by the signal receiving unit to generate first voltage signals. The switch unit connects the power supply unit to an external power in response to receiving the first voltage signals. The control identifies a current mode of the electrical equipment and determines whether the first voltage signal persists longer than a predetermined time or not. The control outputs a second voltage signals in response to the duration time of the first voltage signals being greater than the predetermined time. The switch unit further connects the power supply unit to the external power according to the first voltage signal and the second voltage signal to start the electrical equipment.

Abstract: A smear staining machine and a smearing control method and device thereof. The viscosity of the test sample is used for guiding the configuration of at least one smearing parameter. Because the viscosity of the test sample presents multiple influences of many effecting parameters, it is more suitable for presenting the characteristics of the test sample. Therefore, a better smearing effect could be acquired by referring the viscosity of the test sample to get the smearing parameter.

Abstract: Described are ROR? modulators of the formula (I), [INSERT CHEMICAL STRUCTURE HERE] or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.

Abstract: Described are ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.

Abstract: Described are ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.

Abstract: Described are ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.

Abstract: Described are ROR? modulators of the formula (I), or pharmaceutically acceptable salts thereof, wherein all substituents are defined herein. The invention includes stereoisomeric forms of the compounds of formula I, including stereoisomerically-pure, scalemic and racemic form, as well as tautomers thereof. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.

Abstract: A wireless communication method utilizes a large-scale antenna array, which is deployed at the base station and can be a one-dimensional or two-dimensional array and can form tens of beams over the area covered by the base station. The communications method utilizes beam domain division of spatial resources at the base station side utilizing an analog multi-beam forming network or a digital domain multi-beam forming method. The base station carries out wireless communication with multiple users with the same time frequency resource and with the communications process implemented in the beam domain. Scheduling is accomplished through the utilization of a deterministic unitary matrix to form beams. The unitary matrix is a correlation matrix of interference that includes a channel characteristics mode energy coupling matrix, the beam allocation providing beam sets of different users that are non-overlapping to distinguish users in the beam domain.

Abstract: Described are ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.

Abstract: Described are ROR? modulators of the formula (I), or pharmaceutically acceptable salts thereof, wherein all substituents are defined herein. The invention includes stereoisomeric forms of the compounds of formula I, including stereoisomerically-pure, scalemic and racemic form, as well as tautomers thereof. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.

Abstract: A smart, integrated charging device for electric vehicles is provided. The alternating current input module is connected to an electricity metering module via an alternating current input switch. The charging module is connected to the electricity metering module via a module alternating current switch and an alternating current bus, and is connected to an output monitoring module via a direct current bus. The output monitoring module is connected to the monitoring and general control module. The direct current output module is connected to the output monitoring module via a direct current output switch. The lightning protection module is connected to the direct current bus. The charging module utilizes smart power combination and multiple output coordination to enable output with current sharing and the automatic balance control technology.

Abstract: The embodiments of the present disclosure provide a method and an apparatus for reducing an echo, which apply a first stage adaptive filter to a downlink reference signal to obtain a first stage filtered signal and a first error signal; after performing a K-path gain process and a K-path pre-distortion process to the downlink reference signal, apply the at least one second stage adaptive filter to a K-path pre-distorted signal to obtain a second stage filtered signal and a second error signal; and perform a minimum value fusion process to the first error signal and the second error signal so as to obtain a residue signal, which is considered as a final output of adaptive echo cancellation. Accordingly, the present disclosure realizes steadily providing a relatively high echo loss under a circumstance that a speaker suffers a relatively great distortion.

Abstract: Method and apparatus for reducing distortion echo are provided. K-path amplification and pre-distortion process are performed to the downlink reference signal to obtain K-path pre-distorted signals. Afterwards, filtering is performed using the self-adaptive filters which correspond to the downlink reference signal x(t) and the K-path pre-distorted signals to obtain the filtering signals. Error signals are obtained by calculating differences between the target signal and each of the filtering signals. The minimum-value fusion process is performed to the error signals to obtain the residual signal which is then output as the final self-adaptive echo cancellation. In embodiments of the present disclosure, the residual signal is relatively small as the minimum-value fusion process is performed to the error signals. That is to say, echo loss is relatively great. Therefore, the method may provide echo loss with high amplitude under a situation that a speaker has relatively serious distortion.